UBS Group’s Minerva Neurosciences NERV Stock Holding History

UBS Group’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Buy	67,570 +65,763	+3,639%	+$377K	﹤0.01%	6224
2025 Q4	$7.26K	Buy	1,807 +1,797	+17,970%	+$6.67K	﹤0.01%	8460
2025 Q3	$21	Sell	10 -865	-99%	-$1.77K	﹤0.01%	10128
2025 Q2	$1.5K	Sell	875 -746	-46%	-$1.22K	﹤0.01%	9609
2025 Q1	$2.76K	Buy	1,621 +1,609	+13,408%	+$3.17K	﹤0.01%	9284
2024 Q4	$27	Sell	12 -10,540	-100%	-$24.9K	﹤0.01%	9754
2024 Q3	$28.2K	Buy	10,552 +10,542	+105,420%	+$30.6K	﹤0.01%	7156
2024 Q2	$32	Hold	10	–	–	﹤0.01%	9269
2024 Q1	$26	Sell	10 -55	-85%	-$338	﹤0.01%	9006
2023 Q4	$400	Buy	65 +12	+23%	+$69	﹤0.01%	8683
2023 Q3	$366	Sell	53 -381	-88%	-$3.41K	﹤0.01%	8547
2023 Q2	$3.97K	Buy	+434	New	+$2.29K	﹤0.01%	7584
2022 Q4	–	Sell	-5,732	Closed	-$53K	–	11000
2022 Q3	$53K	Buy	5,732 +5,167	+915%	+$30.6K	﹤0.01%	6301
2022 Q2	$2K	Buy	565 +563	+28,150%	+$2.3K	﹤0.01%	9591
2022 Q1	$0	Hold	2	–	–	﹤0.01%	10677
2021 Q4	$0	Hold	2	–	–	﹤0.01%	10546
2021 Q3	$0	Sell	2 -1,164	-100%	-$17.5K	﹤0.01%	9885
2021 Q2	$22K	Sell	1,166 -2,086	-64%	-$44.9K	﹤0.01%	7238
2021 Q1	$76K	Buy	3,252 +328	+11%	+$8.2K	﹤0.01%	6172
2020 Q4	$55K	Buy	2,924 +2,809	+2,443%	+$70.8K	﹤0.01%	6101
2020 Q3	$3K	Sell	115 -1,089	-90%	-$29.4K	﹤0.01%	7547
2020 Q2	$35K	Sell	1,204 -4,258	-78%	-$250K	﹤0.01%	6168
2020 Q1	$263K	Buy	5,462 +814	+18%	+$49.1K	﹤0.01%	4504
2019 Q4	$265K	Buy	4,648 +2,526	+119%	+$111K	﹤0.01%	5394
2019 Q3	$132K	Buy	+2,122	New	+$120K	﹤0.01%	5584
2019 Q1	–	Sell	-127	Closed	-$7K	–	8006
2018 Q4	$7K	Sell	127 -27	-18%	-$1.98K	﹤0.01%	7418
2018 Q3	$15K	Sell	154 -380	-71%	-$28.6K	﹤0.01%	6968
2018 Q2	$35K	Buy	534 +418	+360%	+$25.4K	﹤0.01%	6281
2018 Q1	$6K	Buy	+116	New	+$5.57K	﹤0.01%	7154
2017 Q4	–	Sell	-785	Closed	-$48K	–	8004
2017 Q3	$48K	Buy	785 +727	+1,253%	+$41.7K	﹤0.01%	5821
2017 Q2	$4K	Buy	58 +28	+93%	+$1.81K	﹤0.01%	7208
2017 Q1	$2K	Sell	30 -233	-89%	-$18.1K	﹤0.01%	7293
2016 Q4	$25K	Buy	263 +8	+3%	+$817	﹤0.01%	6377
2016 Q3	$29K	Buy	+255	New	+$24.7K	﹤0.01%	5967
2016 Q2	–	Sell	-5,894	Closed	-$290K	–	7884
2016 Q1	$290K	Buy	5,894 +5,658	+2,397%	+$242K	﹤0.01%	4209
2015 Q4	$11K	Buy	236 +143	+154%	+$5.97K	﹤0.01%	7230
2015 Q3	$4K	Buy	+93	New	+$4.27K	﹤0.01%	7830

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

UBS Group's NERV Position: Q1 2026 in Review

UBS Group increased its Minerva Neurosciences (NERV) stake by 3,639% in Q1 2026, buying an estimated $377K and bringing the position to 67,570 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #6224.

UBS Group first reported a position in NERV in Q3 2015 and has held it in 37 quarters since. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

UBS Group held 67,570 shares of Minerva Neurosciences worth $407K as of Q1 2026.
UBS Group bought 65,763 Minerva Neurosciences shares in Q1 2026, an estimated $377K.
Minerva Neurosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6224 holding.
UBS Group first reported a position in Minerva Neurosciences in Q3 2015 and has held it in 37 quarters since.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.